- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory multiple myeloma (MM)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 929.1KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 452.6KB)
Belantamab mafodotin – November 2025
Belantamab mafodotin: Powder for injection 70 mg (50 mg per ml) Powder for injection 100 mg (50 mg per ml); Blenrep® - November 2025
Last updated
5 November 2025